J Maertens

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation

Haematologica (2014)

Christian Koenecke Gudrun Göhring L. C. de Wreede Anja van Biezen Christoph Scheid

The aim of this study was to determine the impact of the revised 5-group International Prognostic Scoring System cytogenetic classification on outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for Blood and Marrow Transplantation database. A total of 903 patients had sufficient cytogenetic information available at stem cell transplantation to be classified according to the 5-group classification. Poor and very poor risk according to this classification was an independent predictor of shorter relapse-free survival (hazard ratio 1.40 and 2.14), overall survival (hazard ratio 1.38 and 2.14), and significantly higher cumulative incidence of relapse (hazard ratio 1.64 and 2.76), compared to patients with very good, good or intermediate risk. When comparing the predictive performance of a series of Cox models both for relapse-free survival and for overall survival, a model with simplified 5-group cytogenetics (merging very good, good and intermediate cytogenetics) performed best. Furthermore, monosomal karyotype is an additional negative predictor for outcome within patients of the poor, but not the very poor risk group of the 5-group classification. The revised International Prognostic Scoring System cytogenetic classification allows patients with myelodysplastic syndromes to be separated into three groups with clearly different outcomes after stem cell transplantation. Poor and very poor risk cytogenetics were strong predictors of poor patient outcome. The new cytogenetic classification added value to prediction of patient outcome compared to prediction models using only traditional risk factors or the 3-group International Prognostic Scoring System cytogenetic classification.

Cumulative incidence

10.3324/haematol.2014.116715

Cite

Citations (48)

Myeloid sarcoma as a presentation of acute leukaemia with t(8;21)

G. T. A. Huysmans Chris De Wolf‐Peeters Nancy Boeckx Timothy Devos M Delforge

Presentation (obstetrics)

Myeloid leukaemia

Source

Cite

Citations (0)

Prognostic value of pretransplant positron emission tomography using fluorine-18 fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

Journal of Nuclear Medicine (2003)

Karoline Spaepen Sigrid Stroobants Patrick Dupont Guy Bormans Peter Vandenberghe

Fluorodeoxyglucose

Autologous stem-cell transplantation

Source

Cite

Citations (6)

Nonmyeloablative stem cell transplants: the Belgian Hematological Society Dose-finding Study

Bone Marrow Transplantation (2002)

Dominique Bron Pierre Zachée J Maertens Chantal Doyen Peter Vandenberghe

Hematology

Source

Cite

Citations (0)

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

Bone Marrow Transplantation (2016)

Marie Robin Raphaël Porcher Wilma Zinke-Cerwenka Anja van Biezen Liisa Volin

10.1038/bmt.2016.266

Cite

Citations (44)

A retrospective series of gut aspergillosis in haematology patients

Clinical Microbiology and Infection (2010)

Eyad Kazan J Maertens Raoul Herbrecht Maja Weisser Bertrand Gachot

Galactomannan

Hematology

10.1111/j.1469-0691.2010.03310.x

Cite

Citations (100)

Monosomal karyotype, higher blast count and ex vivo T-cell depletion predict poor outcome after allogeneic stem cell transplantation for MDS/SAML patients with chromosome 7 abnormalities

Bone Marrow Transplantation (2010)

M. van Gelder Johannes Schetelig Liisa Volin J Maertens Gèrard Socié

Ex vivo

Source

Cite

Citations (0)

High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

Biology of Blood and Marrow Transplantation (2011)

Nicolas Mounier Carmen Canals Christian Gisselbrecht Jan J. Cornelissen Roberto Foá

Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patients with relapsed diffuse large B cell lymphoma. The impact of rituximab combined with chemotherapy in either first- or second-line therapy on the ultimate results of ASCT remains to be determined, however. This study was designed to evaluate the benefit of ASCT in patients achieving a second complete remission after salvage chemotherapy by retrospectively comparing the disease-free survival (DFS) after ASCT for each patient with the duration of the first complete remission (CR1). Between 1990 and 2005, a total of 470 patients who had undergone ASCT and reported to the European Blood and Bone Transplantation Registry with Medical Essential Data Form B information were evaluated. Of these 470 patients, 351 (74%) had not received rituximab before ASCT, and 119 (25%) had received rituximab before ASCT. The median duration of CR1 was 11 months. The median time from diagnosis to ASCT was 24 months. The BEAM protocol was the most frequently used conditioning regimen (67%). After ASCT, the 5-year overall survival was 63% (95% confidence interval, 58%-67%) and 5-year DFS was 48% (95% confidence interval, 43%-53%) for the entire patient population. Statistical analysis showed a significant increase in DFS after ASCT compared with duration of CR1 (median, 51 months versus 11 months; P < .001). This difference was also highly significant for patients with previous exposure to rituximab (median, 10 months versus not reached; P < .001) and for patients who had experienced relapse before 1 year (median, 6 months versus 47 months; P < .001). Our data indicate that ASCT can significantly increase DFS compared with the duration of CR1 in relapsed diffuse large B cell lymphoma and can alter the disease course even in patients with high-risk disease previously treated with rituximab. Autologous stem cell transplantation (ASCT) consolidation remains the treatment of choice for patients with relapsed diffuse large B cell lymphoma. The impact of rituximab combined with chemotherapy in either first- or second-line therapy on the ultimate results of ASCT remains to be determined, however. This study was designed to evaluate the benefit of ASCT in patients achieving a second complete remission after salvage chemotherapy by retrospectively comparing the disease-free survival (DFS) after ASCT for each patient with the duration of the first complete remission (CR1). Between 1990 and 2005, a total of 470 patients who had undergone ASCT and reported to the European Blood and Bone Transplantation Registry with Medical Essential Data Form B information were evaluated. Of these 470 patients, 351 (74%) had not received rituximab before ASCT, and 119 (25%) had received rituximab before ASCT. The median duration of CR1 was 11 months. The median time from diagnosis to ASCT was 24 months. The BEAM protocol was the most frequently used conditioning regimen (67%). After ASCT, the 5-year overall survival was 63% (95% confidence interval, 58%-67%) and 5-year DFS was 48% (95% confidence interval, 43%-53%) for the entire patient population. Statistical analysis showed a significant increase in DFS after ASCT compared with duration of CR1 (median, 51 months versus 11 months; P < .001). This difference was also highly significant for patients with previous exposure to rituximab (median, 10 months versus not reached; P < .001) and for patients who had experienced relapse before 1 year (median, 6 months versus 47 months; P < .001). Our data indicate that ASCT can significantly increase DFS compared with the duration of CR1 in relapsed diffuse large B cell lymphoma and can alter the disease course even in patients with high-risk disease previously treated with rituximab.

Autologous stem-cell transplantation

Regimen

Salvage therapy

10.1016/j.bbmt.2011.10.010

Cite

Citations (110)

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Blood (2006)

Rodrigo Martino Rocío Parody Takahiro Fukuda J Maertens Koen Theunissen

Cumulative incidence

10.1182/blood-2006-03-008706

Cite

Citations (129)

Endodermal sinus tumor of the vulva: successfully treated with high-dose chemotherapy

International Journal of Gynecological Cancer (2004)

Koen Traen Hilde Logghe J Maertens C. Mattelaere Philippe Moerman

Endodermal sinus tumors (EST) of the lower female genital tract are uncommon malignancies. Most of these tumors are found in the vagina or in the cervix. Only seven cases of EST involving the vulva are reported. We report an eighth case of vulvar EST. The patient recurred and was successfully treated with high-dose chemotherapy and peripheral blood cell transplantation. Because of their location, an early diagnosis of vulvar EST should be possible. Resection of the lesion by using a modified radical vulvectomy followed by cisplatin-based chemotherapy seems the best treatment for these tumors today. Our patient was initially treated with the help of local surgery and adjuvant chemotherapy consisting of three courses of etoposide and cisplatin. Sixteen months after the first diagnosis, pleural and lung metastases were diagnosed. Second-line chemotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell support was administered after resection of the lung metastases and biopsy of the pleural metastases. There is no evidence of disease 40 months after the diagnosis of the lung and pleural metastases, and 56 months after the primary diagnosis.

10.1111/j.1048-891x.2004.14540.x

Cite

Citations (15)